Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01120691
Other study ID # CQVA149A2304
Secondary ID 2009-013256-69
Status Completed
Phase Phase 3
First received May 5, 2010
Last updated October 29, 2013
Start date April 2010
Est. completion date July 2012

Study information

Verified date October 2013
Source Novartis
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationArgentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia MedicaAustralia: Department of Health and Ageing Therapeutic Goods AdministrationBelgium: Federal Agency for Medicinal Products and Health ProductsBrazil: National Health Surveillance AgencyCanada: Health CanadaChile: Comisión Nacional de Investigación Científica y TecnológicaColombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y AlimentosCzech Republic: State Institute for Drug ControlDenmark: Danish Medicines AgencyEstonia: The State Agency of MedicineFinland: Finnish Medicines AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)Germany: Federal Institute for Drugs and Medical DevicesGreece: National Organization of MedicinesGuatemala: Ministry of Public Health and Social AssistanceHungary: National Institute of PharmacyIndia: Drugs Controller General of IndiaIreland: Irish Medicines BoardIsrael: Ministry of HealthItaly: The Italian Medicines AgencyKorea: Food and Drug AdministrationMalaysia: Ministry of HealthMexico: Ministry of HealthNetherlands: Medicines Evaluation Board (MEB)New Zealand: Food Safety AuthorityNorway: Norwegian Medicines AgencyPeru: Ministry of HealthPhilippines: Bureau of Food and DrugsPoland: Ministry of HealthRomania: National Medicines AgencyRussia: Ministry of Health of the Russian FederationSingapore: Health Sciences AuthoritySouth Africa: Department of HealthSpain: Spanish Agency of MedicinesThailand: Food and Drug AdministrationTurkey: Ministry of HealthUkraine: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.


Recruitment information / eligibility

Status Completed
Enrollment 2224
Est. completion date July 2012
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Both
Age group 40 Years and older
Eligibility Inclusion Criteria :

1. Male or female adults aged =40 years, who had signed an informed consent form prior to initiation of any study-related procedure.

2. Patients with severe to very severe Chronic Obstructive Pulmonary Disease COPD (Stage III or IV) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.

3. Current or ex-smokers with a smoking history of at least 10 pack years (Ten pack-years were defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years).

4. Patients with a post-bronchodilator Forced Expiratory Volume in one second ( FEV1) <50% of the predicted normal value, and post-bronchodilator FEV1/ Forced Vital Capacity (FVC) <0.70 at Visit 2 (day -14). (Post refers to 1 h after sequential inhalation of 84 µg (or equivalent dose) of ipratropium bromide and 400 µg of salbutamol).

5. A documented history of at least 1 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticosteroids and/or antibiotics.

Exclusion Criteria:

1. Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy test).

2. Women of child-bearing potential

3. Patients requiring long term oxygen therapy (> 15 h a day) on a daily basis for chronic hypoxemia.

4. Patients who had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the 6 weeks prior to visit 1 or between visit 1 (Day -21) and Visit 3 (Day 1).

5. Patients who developed a COPD exacerbation during a period between visit 1 and 3 were ineligible but were permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation.

6. Patients who had a respiratory tract infection within 4 weeks prior to visit 1 (Day -21)

• Patients who developed an upper or lower respiratory tract infection during the screening period (up to visit 3 (Day 1) were not eligible, but were permitted to be re-screened 4 weeks after the resolution of the respiratory tract infection

7. Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless confirmed by chest x-ray to be no longer active), clinically significant bronchiectasis, sarcoidosis, interstitial lung disorder or pulmonary hypertension.

8. Patients with lung lobectomy, or lung volume reduction or lung transplantation.

9. Patients who, in the judgment of the investigator, have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to):

- Unstable ischemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding chronic stable Atrial Fibrillation (AF). Patients with such events not considered clinically significant by the investigator may be considered for inclusion in the study

- history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin

- uncontrolled hypo- or hyperthyroidism, hypokalemia or hyper adrenergic state

- narrow-angle glaucoma

- Symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention. (Patients with a Transurethral Resection of Prostate (TURP) were excluded from the study. Patients who underwent full re-section of the prostate could be considered for the study, as well as patients who were asymptomatic and stable on pharmacological treatment for the condition).

- any condition which might have compromised patient safety or compliance, interfered with evaluation, or precluded completion of the study

10. Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count > 600/mm3 (at visit 2), or onset of symptoms prior to 40 years. Patients without asthma were excluded if their eosinophil count was >600/mm3 at visit 2.

11. Patients with allergic rhinitis who used H1 antagonists or intranasal corticosteroids intermittently (treatment with a constant dose was permitted).

12. Patients with eczema (atopic), known high immunoglobulin E (IgE) levels or a known positive skin prick test in the last 5 years.

13. Patients with known history and diagnosis of alpha-1 antitrypsin deficiency.

14. Patients who were participating in the active phase of a supervised pulmonary rehabilitation program.

15. Patients with Type I or uncontrolled Type II diabetes.

16. Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the following inhaled drugs or drugs of a similar class or any component thereof:

- anticholinergic agents

- long and short acting beta-2 agonists

- sympathomimetic amines.

17. Patients with a history of long QT syndrome or whose corrected QT interval (QTc) measured at visit 2 (Day -14) (Fridericia method) was prolonged (>450 ms for males and females) as confirmed by the central ECG assessor.

18. Patients with a clinically significant abnormality on the screening or baseline ECG who in the judgment of the investigator would be at potential risk if enrolled into the study. (These patients could not be re-screened).

19. Patients who needed treatments for COPD and allied conditions after the start of the study (visit 1)

20. Patients who needed treatments for COPD and allied conditions (e.g. allergic rhinitis) unless they had been stabilized

21. Patients taking other prohibited medications

22. Patients unable to use a dry powder inhaler (e.g. single dose dry powder inhaler (SDDPI), HandiHaler® device, or pressurized Metered Dose Inhaler (MDI) (rescue medication).

23. Patients unable to use an electronic patient diary.

24. Patients who were, in the opinion of the investigator known to be unreliable or non-compliant.

25. Patients who used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of visit 1 (day -21), whichever was longer.

26. Patients who had live attenuated vaccination within 30 days prior to the screening visit or during the run-in period. Inactivated influenza vaccination, pneumococcal vaccination or any other inactivated vaccine was acceptable provided it was not administered within 48 hours prior to screening and randomization visits.

No additional exclusions were applied by the investigator, in order to ensure that the study population was representative of all eligible patients.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
QVA149
QVA149 110/50 µg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
NVA237
NVA237 50 µg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
tiotropium
Open-label tiotropium bromide 18 µg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Salbutamol/albuterol
As needed throughout the study

Locations

Country Name City State
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos aires
Argentina Novartis Investigative Site Buenos aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Buenos Aires
Argentina Novartis Investigative Site Capital Federal Buenos Aires
Argentina Novartis Investigative Site Cordoba
Argentina Novartis Investigative Site Corrientes
Argentina Novartis Investigative Site La Plata Buenos Aires
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Mar del Plata Buenos Aires
Argentina Novartis Investigative Site Mendoza
Argentina Novartis Investigative Site Mendoza
Argentina Novartis Investigative Site Paraná Entre Ríos
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site Rosario Santa Fe
Argentina Novartis Investigative Site San Isidro Buenos Aires
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site San Miguel de Tucuman Tucuman
Argentina Novartis Investigative Site Santa Fe
Austria Novartis Investigative Site Feldbach
Austria Novartis Investigative Site Grieskirchen
Austria Novartis Investigative Site Linz
Austria Novartis Investigative Site Salzburg
Austria Novartis Investigative Site Thalheim bei Wels
Canada Novartis Investigative Site Edmonton Alberta
Canada Novartis Investigative Site Joliette Quebec
Canada Novartis Investigative Site Laval Quebec
Canada Novartis Investigative Site Mississauga Ontario
Canada Novartis Investigative Site Montreal Quebec
Canada Novartis Investigative Site Ottawa Ontario
Canada Novartis Investigative Site Quebec
Canada Novartis Investigative Site Québec Quebec
Canada Novartis Investigative Site St-Romuald Quebec
Canada Novartis Investigative Site Trois-Rivières Quebec
Colombia Novartis Investigative Site Armenia
Colombia Novartis Investigative Site Barranquilla
Colombia Novartis Investigative Site Bogota Cundinamarca
Colombia Novartis Investigative Site Bogotá
Colombia Novartis Investigative Site Medellin
Colombia Novartis Investigative Site Medellín
Czech Republic Novartis Investigative Site Cesky Krumlov
Czech Republic Novartis Investigative Site Cvikov
Czech Republic Novartis Investigative Site Havlickuv Brod
Czech Republic Novartis Investigative Site Jaromer
Czech Republic Novartis Investigative Site Karlovy Vary
Czech Republic Novartis Investigative Site Kromeriz
Czech Republic Novartis Investigative Site Kutna Hora
Czech Republic Novartis Investigative Site Kyjov
Czech Republic Novartis Investigative Site Liberec
Czech Republic Novartis Investigative Site Pardubice
Czech Republic Novartis Investigative Site Prague 4
Czech Republic Novartis Investigative Site Praha 10
Czech Republic Novartis Investigative Site Praha 9
Czech Republic Novartis Investigative Site Rokycany
Czech Republic Novartis Investigative Site Strakonice
Czech Republic Novartis Investigative Site Teplice
Czech Republic Novartis Investigative Site Zatec
Czech Republic Novartis Investigative Site Znojmo
Denmark Novartis Investigative Site Aalborg
Denmark Novartis Investigative Site Copenhagen NV
Denmark Novartis Investigative Site Hellerup
Denmark Novartis Investigative Site Hvidovre
Denmark Novartis Investigative Site Roskilde
Denmark Novartis Investigative Site Silkeborg
Denmark Novartis Investigative Site Sønderborg
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tartu
Finland Novartis Investigative Site Helsinki
Finland Novartis Investigative Site Jyvaskyla
Finland Novartis Investigative Site Turku
France Novartis Investigative Site Bayonne Cedex
France Novartis Investigative Site Beuvry
France Novartis Investigative Site Ferolles-Attily
France Novartis Investigative Site Montpellier
France Novartis Investigative Site Paris
Germany Novartis Investigative Site Aschaffenburg
Germany Novartis Investigative Site Bamberg
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bochum
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dueren
Germany Novartis Investigative Site Duisburg
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Freudenberg
Germany Novartis Investigative Site Fulda
Germany Novartis Investigative Site Gelsenkirchen
Germany Novartis Investigative Site Gummersbach
Germany Novartis Investigative Site Hagen
Germany Novartis Investigative Site Halle
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hannover
Germany Novartis Investigative Site Heidelberg
Germany Novartis Investigative Site Homburg
Germany Novartis Investigative Site Kiel
Germany Novartis Investigative Site Koblenz NRW
Germany Novartis Investigative Site Langenfeld
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Lübeck
Germany Novartis Investigative Site Marburg
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Nuernberg
Germany Novartis Investigative Site Oranienburg
Germany Novartis Investigative Site Potsdam
Germany Novartis Investigative Site Radebeul
Germany Novartis Investigative Site Reinfeld
Germany Novartis Investigative Site Saarbruecken
Germany Novartis Investigative Site Schwerte
Germany Novartis Investigative Site Schwetzingen
Germany Novartis Investigative Site Solingen
Germany Novartis Investigative Site Stade
Germany Novartis Investigative Site Teterow
Germany Novartis Investigative Site Wissen
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens
Greece Novartis Investigative Site Athens - GR
Greece Novartis Investigative Site Larissa
Greece Novartis Investigative Site Thessaloniki
Greece Novartis Investigative Site Thessaloniki
Hungary Novartis Investigative Site Baja
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Cegled
Hungary Novartis Investigative Site Debrecen
Hungary Novartis Investigative Site Deszk
Hungary Novartis Investigative Site Eger
Hungary Novartis Investigative Site Makó
Hungary Novartis Investigative Site Mosonmagyarovar
Hungary Novartis Investigative Site Sopron
Hungary Novartis Investigative Site Szarvas
Hungary Novartis Investigative Site Szekszard
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site Coimbatore Tamil Nadu
India Novartis Investigative Site Hyderabad A.p.
India Novartis Investigative Site Hyderbabd Andhra Pradesh
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Mysore Karnataka
India Novartis Investigative Site Nagpur - Maharastra
India Novartis Investigative Site Nashik Maharashtra
India Novartis Investigative Site New Delhi Delhi
India Novartis Investigative Site Panjim
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Secunderabad
India Novartis Investigative Site Trivandrum
Ireland Novartis Investigative Site Dublin
Ireland Novartis Investigative Site Dublin 15
Ireland Novartis Investigative Site Dublin 24
Ireland Novartis Investigative Site Dublin 4
Ireland Novartis Investigative Site Dublin 9
Israel Novartis Investigative Site Ashkelon
Israel Novartis Investigative Site Beer-Sheva
Israel Novartis Investigative Site Jerusalem
Israel Novartis Investigative Site Jerusalem
Israel Novartis Investigative Site Kfar-Sava
Israel Novartis Investigative Site Petach Tikva
Israel Novartis Investigative Site Ramat Gan
Israel Novartis Investigative Site Rehovot
Israel Novartis Investigative Site Tel-Aviv
Italy Novartis Investigative Site Abano Terme PD
Italy Novartis Investigative Site Arenzano GE
Italy Novartis Investigative Site Catania CT
Italy Novartis Investigative Site Firenze FI
Italy Novartis Investigative Site Foggia FG
Italy Novartis Investigative Site Milano MI
Italy Novartis Investigative Site Montecchio Maggiore VI
Italy Novartis Investigative Site Osimo AN
Italy Novartis Investigative Site Pavia PV
Italy Novartis Investigative Site Perugia PG
Italy Novartis Investigative Site Pietra Ligure SV
Italy Novartis Investigative Site Pisa
Italy Novartis Investigative Site Pisa PI
Italy Novartis Investigative Site Riccione RN
Italy Novartis Investigative Site Roma RM
Italy Novartis Investigative Site Siena SI
Mexico Novartis Investigative Site Guadalajara Jalisco
Mexico Novartis Investigative Site Mexico Distrito Federal
Mexico Novartis Investigative Site Mexico Distrito Federal
Mexico Novartis Investigative Site Monterrey Nuevo León
Mexico Novartis Investigative Site San Luis Potosí
Mexico Novartis Investigative Site Zapopan Jalisco
Netherlands Novartis Investigative Site Almelo
Netherlands Novartis Investigative Site Breda
Netherlands Novartis Investigative Site Dordrecht
Netherlands Novartis Investigative Site Drachten
Netherlands Novartis Investigative Site Enschede
Netherlands Novartis Investigative Site Harderwijk
Netherlands Novartis Investigative Site Helmond
Netherlands Novartis Investigative Site Hoofddorp
Netherlands Novartis Investigative Site Hoorn
Netherlands Novartis Investigative Site Leeuwarden
Netherlands Novartis Investigative Site Roermond
Netherlands Novartis Investigative Site Veldhoven
Netherlands Novartis Investigative Site Voorburg
Peru Novartis Investigative Site Cercado de Lima Lima
Peru Novartis Investigative Site San Borja Lima
Peru Novartis Investigative Site San Isidro Lima
Peru Novartis Investigative Site San Martin de Porres Lima
Peru Novartis Investigative Site San Miguel Lima
Peru Novartis Investigative Site Santiago de Surco Lima
Philippines Novartis Investigative Site Bulacan
Philippines Novartis Investigative Site Las Pinas
Philippines Novartis Investigative Site Manila
Philippines Novartis Investigative Site Quezon City
Philippines Novartis Investigative Site Quezon City Metro Manila
Poland Novartis Investigative Site Bialystok
Poland Novartis Investigative Site Katowice
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Lublin
Poland Novartis Investigative Site Mrozy
Poland Novartis Investigative Site Warszawa
Puerto Rico Novartis Investigative Site Humacao
Russian Federation Novartis Investigative Site Barnaul
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Ekaterinburg
Russian Federation Novartis Investigative Site Kazan Tatarstan Republic
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Rostov-on-Don
Russian Federation Novartis Investigative Site Ryazan
Russian Federation Novartis Investigative Site S.-Petersburg
Russian Federation Novartis Investigative Site Samara
Russian Federation Novartis Investigative Site Sankt-Peterburg
Russian Federation Novartis Investigative Site St-Petersburg
Russian Federation Novartis Investigative Site St. Petersburg
Russian Federation Novartis Investigative Site St. Petersburg
Russian Federation Novartis Investigative Site St. Petersburg
Russian Federation Novartis Investigative Site St.Petersburg
Russian Federation Novartis Investigative Site Yaroslavl
Slovakia Novartis Investigative Site Banska Bystrica Slovak Republic
Slovakia Novartis Investigative Site Bojnice Slovak Republic
Slovakia Novartis Investigative Site Humenne Slovak Republic
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Kralovsky Chlmec
Slovakia Novartis Investigative Site Martin
Slovakia Novartis Investigative Site Partizanske Slovak Republic
Slovakia Novartis Investigative Site Presov
Slovakia Novartis Investigative Site Trnava
South Africa Novartis Investigative Site Durban
South Africa Novartis Investigative Site Newtown, Johannesburg
South Africa Novartis Investigative Site Pretoria
South Africa Novartis Investigative Site Pretoria
South Africa Novartis Investigative Site Pretoria
Spain Novartis Investigative Site Alicante
Spain Novartis Investigative Site L'Hospitalet de Llobregat Cataluña
Spain Novartis Investigative Site La Coruna Galicia
Spain Novartis Investigative Site Malaga Andalucia
Spain Novartis Investigative Site Valencia Comunidad Valenciana
United Kingdom Novartis Investigative Site Blackpool
United Kingdom Novartis Investigative Site Bradford
United Kingdom Novartis Investigative Site Bristol
United Kingdom Novartis Investigative Site Chertsey Surrey
United Kingdom Novartis Investigative Site Coventry
United Kingdom Novartis Investigative Site Gillingham
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site Hereford
United Kingdom Novartis Investigative Site Huntingdon
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Manchester
United Kingdom Novartis Investigative Site Merseyside
United Kingdom Novartis Investigative Site Portsmouth
United Kingdom Novartis Investigative Site Sneinton Nottingham
United Kingdom Novartis Investigative Site Stockton Cleveland
United Kingdom Novartis Investigative Site Taunton Somerset
United Kingdom Novartis Investigative Site Telford
United Kingdom Novartis Investigative Site Wolverhampton
United States Novartis Investigative Site Bangor Maine
United States Novartis Investigative Site Beaver Pennsylvania
United States Novartis Investigative Site Birmingham Alabama
United States Novartis Investigative Site Charleston South Carolina
United States Novartis Investigative Site Charlotte North Carolina
United States Novartis Investigative Site Columbus Ohio
United States Novartis Investigative Site Couer D'Alene Idaho
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Erie Pennsylvania
United States Novartis Investigative Site Fairhope Alabama
United States Novartis Investigative Site Florence Alabama
United States Novartis Investigative Site Florence Kentucky
United States Novartis Investigative Site Fort Worth Texas
United States Novartis Investigative Site Fridley Minnesota
United States Novartis Investigative Site Ft. Worth Texas
United States Novartis Investigative Site Fullerton California
United States Novartis Investigative Site Gainesville Florida
United States Novartis Investigative Site Great Neck New York
United States Novartis Investigative Site Green Bay Wisconsin
United States Novartis Investigative Site Henderson Nevada
United States Novartis Investigative Site Homewood Alabama
United States Novartis Investigative Site Jasper Alabama
United States Novartis Investigative Site Las Vegas Nevada
United States Novartis Investigative Site Louisville Kentucky
United States Novartis Investigative Site Massapequa New York
United States Novartis Investigative Site Medford Oregon
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Missoula Montana
United States Novartis Investigative Site Normal Illinois
United States Novartis Investigative Site Opelousas Louisiana
United States Novartis Investigative Site Ozark Missouri
United States Novartis Investigative Site Palo Alto California
United States Novartis Investigative Site Papillion Nebraska
United States Novartis Investigative Site Pensacola Florida
United States Novartis Investigative Site Pine Bluff Arkansas
United States Novartis Investigative Site Pittsburgh Pennsylvania
United States Novartis Investigative Site Portland Oregon
United States Novartis Investigative Site Raleigh North Carolina
United States Novartis Investigative Site Reno Nevada
United States Novartis Investigative Site River Forest Illinois
United States Novartis Investigative Site Riverside California
United States Novartis Investigative Site Salem Virginia
United States Novartis Investigative Site Salt Lake City Utah
United States Novartis Investigative Site San Diego California
United States Novartis Investigative Site San Diego California
United States Novartis Investigative Site San Diego California
United States Novartis Investigative Site Spartanburg South Carolina
United States Novartis Investigative Site St. Charles Missouri
United States Novartis Investigative Site St. Louis Missouri
United States Novartis Investigative Site Stockton California
United States Novartis Investigative Site Tacoma Washington
United States Novartis Investigative Site Wilmington North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Argentina,  Austria,  Canada,  Colombia,  Czech Republic,  Denmark,  Estonia,  Finland,  France,  Germany,  Greece,  Hungary,  India,  Ireland,  Israel,  Italy,  Mexico,  Netherlands,  Peru,  Philippines,  Poland,  Puerto Rico,  Russian Federation,  Slovakia,  South Africa,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years
64 weeks No
Secondary Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and Open-label Tiotropium Treatment Arms During the Treatment Period. A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years
76 weeks No
Secondary Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Between QVA149, NVA237 and Open Label Tiotropium During the Treatment Period A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.
Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years
64 weeks No
Secondary Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Requiring the Use of Both Systemic Glucocorticosteroids and Antibiotics Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years 64 weeks No
Secondary Number of Days With Moderate or Severe Exacerbation That Required Treatment With Systemic Corticosteroids and Antibiotics The number of exacerbation days is defined as the sum of the duration of days recorded as an exacerbation for all exacerbations recorded per patient. 64 weeks No
Secondary Time to Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.) During the Treatment Period. Time to Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase. 64 weeks No
Secondary Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.)During the Treatment Period Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase. 64 weeks No
Secondary Cumulative Rates of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations for Multiple COPD Exacerbation at Different Time Points Cumulative rates were estimated using Anderson and Gill method. Chronic Obstructive Pulmonary Disease (COPD) exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required. Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years 26, 52, 64, 76 weeks No
Secondary Pre-dose Forced Expiratory Volume in 1 Second (FEV-1) After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.
Spirometry measurements taken were FEV1 at -45 minutes and -15 minutes pre-dose. Three acceptable maneuvers had to be performed for each time point. The FEV1 values recorded had to be the highest values measured irrespective of whether or not they occurred on the same curve.
The mixed model for analysis contained treatment as a fixed effect with average of the 45 minutes and 15 minutes pre dose FEV1 measurements at day 1 as the baseline measurement, FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at -14 Day) as covariates.
4, 12, 26, 38, 52 and 64 weeks No
Secondary Pre-dose Forced Vital Capacity (FVC)After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.
Pre-dose Forced Vital Capacity (FVC) is defined as the average of the -15 minutes and the -45 minutes FVC values. Baseline is defined as the average of the -45 minutes and -15 minutes FVC values taken on day 1 prior to first dose. FVC data taken within 6h of rescue medication or within 7 days of systemic corticosteroid is excluded from this analysis
4, 12, 26, 38, 52 and 64 weeks No
Secondary Change in Mean Daily Use (Number of Puffs) of Rescue Therapy Between QVA149, NVA237 and Open Label Tiotropium From Baseling Over the 64 Week Treatment Period The severe or less FEV1 % predicted (post bronchodilator)>=30%; very severe=> FEV1 % predicted(the post bronchodilator)<30%.Number of puffs of rescue medication taken in the previous 12 hours was recorded in patient diary in the morning and in the evening for 26 weeks.The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient.Rescue medication data recorded during the 14 day run-in was used to calculate the baseline.A negative change from baseline indicates improvement. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. Baseline (14 day run-in), 64 weeks No
Secondary Change From Baseline of Percentage of Days Without Rescue Therapy Use Between QVA149,NVA237 and Open Label Tiotropium Over the 64 Week Treatment Period A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. The percentage of days is calculated by the number of days with no rescue medicine use/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect. Baseline (14 day run-in), 64 weeks No
Secondary St. George's Respiratory Questionnaire (SGRQ) Scores Between QVA149, NVA237 and Open Label Tiotropium Over 12, 26, 38, 52 and 64 Weeks of Treatment St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, Forced Expiratory Volume in 1 Second (FEV1) prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates. SGRQ total score is the sum of the scores from the three components; symptoms, activity and impacts. 12, 26, 38, 52 and 64 weeks No
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy